Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug
Merck KGaA is spending $85 million to tap global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from China’s Abbisko Therapeutics in 2023. The German...
View ArticleBefore Alumis went public via IPO, it tried doing a reverse merger with Acelyrin
Last month's all-stock merger proposal between Alumis and Acelyrin wasn't the first time the companies considered a deal. A Thursday SEC filing reveals how, almost a year ago, Alumis approached...
View ArticleOn the heels of staff cuts, CRISPR Therapeutics COO departs; Changes galore...
→ After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's departure comes nearly a month after the gene editing company ...
View ArticleNovo makes oral obesity drug partnership with Lexicon worth up to $1B
Novo Nordisk is going all-in on next-generation obesity medicines, and on Friday announced a licensing deal with a Texas biotech to get access to its oral small molecule drug. Under the deal, Lexicon...
View ArticleBioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive...
BioNTech has highly encouraging survival data for its bispecific antibody combining checkpoint blockade with VEGF-A inhibition as a first-line treatment for a serious form of lung cancer. And if the...
View ArticleEuropean regulator rejects Lilly's Alzheimer’s drug over side effects
Eli Lilly’s Alzheimer’s drug Kisunla has failed to get support from the European Medicines Agency over serious side effects and three patient deaths. The agency’s human medicines committee (CHMP)...
View ArticleDBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor...
Plus, news about Palatin, Spero and BioAtla: DBV Technologies’ $306M financing: The French biotech could get up to that amount to help advance its peanut allergy patch for children through an ...
View ArticleMilestone's shares dive after FDA again rejects drug for abnormal heart rhythm
Milestone Pharmaceuticals’ nasal spray failed for a second time to secure US approval to treat an arrhythmia disorder called paroxysmal supraventricular tachycardia. The FDA’s complete response letter...
View ArticleCHMP acts on Opdivo, Tevimbra, Xoanacyl, Kisunla and others
Bristol Myers Squibb, BeiGene, AstraZeneca and Pfizer secured European backing for label expansions, and a French pharma got its first drug approval recommendation, in a list of actions by the European...
View ArticleJ&J wins patent feud against Viatris over schizophrenia drug
Johnson & Johnson scored an appeals court win in its bid to block generic competition for its long-acting schizophrenia drug. The US Court of Appeals for the Federal Circuit on Friday
View ArticleFDA approves Sanofi's RNAi drug for hemophilia A and B
The FDA on Friday said it approved a new RNAi-based hemophilia treatment from Sanofi that the company licensed from Alnylam. Patients with hemophilia A or B will now be able to ...
View ArticleNovartis’ radiopharma drug Pluvicto gets an expanded label
Novartis’ prostate cancer radiopharmaceutical Pluvicto has netted a highly anticipated and highly delayed expanded indication. The FDA on Friday approved the drug for certain patients before they have...
View ArticleAmgen loses challenge to Colorado drug review board
A federal judge on Friday dismissed Amgen’s lawsuit against Colorado's drug affordability board and its call for a price cap on the company's blockbuster autoimmune drug. District Judge Nina Wang...
View ArticleBluebird gets new M&A bid, seeking to top private equity offer
A rival group is seeking to buy cell therapy biotech bluebird bio, in an effort to outbid a private equity offer by Carlyle and SK Capital, the company confirmed on Friday afternoon. The rival buying ...
View ArticleLykos’ interim CEO is set to step down
Lykos Therapeutics’ interim CEO Michael Mullette is planning to step down, according to a source familiar with the decision. Mullette relayed the move to staff in February, saying that he would stay on...
View ArticleCOVID research cuts target work on antivirals and vaccines to prevent future...
On Tuesday, drug discoverer and biotech entrepreneur Alpha Lee told scientists at a chemistry meeting about a new molecule to combat the Zika virus. There are no treatments designed to stop the...
View ArticleFDA's Peter Marks resigns, in disagreement with Kennedy
Peter Marks, the head of the FDA's Center for Biologics Evaluation and Research and one of the agency's highest-profile officials, has suddenly resigned amid a simmering disagreement with the Trump...
View ArticleHHS cuts and more from DC; Lyndra winds down; 23andMe files for bankruptcy;...
Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The Senate confirmed nominations this week for Johns Hopkins researcher Marty...
View ArticleVertex’s second-generation diabetes cell therapy fails early-stage study
Vertex Pharmaceuticals announced Friday afternoon that it won't move forward with its type 1 diabetes cell therapy that's delivered in a device meant to get rid of the need for immunosuppression ...
View ArticleExclusive: SV Health debuts Parkinson's biotech with backing from AbbVie and...
SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time to advance new Parkinson's disease treatments. The London-based healthcare...
View Article